FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology. Presented is anti-human 4-1BB antibody and its antigen-binding fragment. Invention also relates to a pharmaceutical composition for treating a malignant neoplasm containing anti-human 4-1BB antibody or a fragment thereof.
EFFECT: antibody of the invention has improved properties relative to the reference human anti-human 4-1BB antibody, that is improved binding affinity, improved induction of T-cell proliferation and IFNγ secretion by T-cells, as well as improved capacity to reduce or eliminate malignant growth in vivo.
14 cl, 22 dwg, 7 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODIES AGAINST HUMAN 4-1BB AND THEIR USE | 2018 |
|
RU2777573C2 |
| ANTIBODIES AGAINST TNFRSF9 AND THEIR USE | 2019 |
|
RU2812200C2 |
| ANTI-HER2/ANTI-4-1BB BISPECIFIC ANTIBODY AND USE THEREOF | 2020 |
|
RU2831838C2 |
| BISPECIFIC ANTI-EGFR/ANTI-4-1BB ANTIBODY AND USE THEREOF | 2020 |
|
RU2831836C2 |
| ANTIBODIES AGAINST HUMAN VSIG4 AND APPLICATION THEREOF | 2019 |
|
RU2776638C1 |
| NK-CELL ACTIVATING FUSED PROTEIN, NK-CELLS AND A PHARMACEUTICAL COMPOSITION CONTAINING THEM | 2018 |
|
RU2740438C1 |
| NOVEL ANTI-CLDN18.2 ANTIBODIES | 2020 |
|
RU2830887C2 |
| ANTIBODIES AGAINST OX40 AND THEIR USE | 2017 |
|
RU2783314C2 |
| ANTI-αvβ8 ANTIBODIES AND COMPOSITIONS AND THEIR USE | 2019 |
|
RU2812478C2 |
| ANTIBODIES AGAINST CD40 AND THEIR USE | 2018 |
|
RU2796413C2 |
